Get the Stockscreener App
1.89
0.53%
0.01
Casi Pharmaceuticals Inc stock is traded at $1.89, with a volume of 4,018.
It is up +0.53% in the last 24 hours and down -5.26% over the past month.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
See More
Previous Close:
$1.88
Open:
$1.92
24h Volume:
4,018
Relative Volume:
0.45
Market Cap:
$29.28M
Revenue:
$22.06M
Net Income/Loss:
$-30.94M
P/E Ratio:
-0.8438
EPS:
-2.24
Net Cash Flow:
$-26.70M
1W Performance:
+1.07%
1M Performance:
-5.26%
6M Performance:
-50.26%
1Y Performance:
-45.38%
1-Day Range:
$1.89
$1.92
1-Week Range:
$1.7725
$1.92
52-Week Range:
$1.635
$7.67
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Name
Casi Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare CASI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
1.89 | 28.97M | 22.06M | -30.94M | -26.70M | -2.24 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Initiated | Mizuho | Buy |
| Oct-23-20 | Initiated | Oppenheimer | Outperform |
| Sep-22-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
View All
Casi Pharmaceuticals Inc Stock (CASI) Latest News
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World
HC Wainwright Has Positive Forecast for CASI Q2 Earnings - Defense World
Transcript : CASI Pharmaceuticals, Inc.Special Call - marketscreener.com
CASI to Host Business and Clinical Update Conference Call | CASI Stock News - GuruFocus
CASI Pharmaceuticals Schedules Business Update Amid Legal Proceedings - TipRanks
CASI Pharmaceuticals (NASDAQ:CASI) Given “Buy” Rating at HC Wainwright - Defense World
CASI Pharmaceuticals: HC Wainwright & Co. Reiterates Buy Rating - GuruFocus
CASI Pharmaceuticals Provides Business and Clinical Update - ACCESS Newswire
CASI Pharmaceuticals Schedules Major Business and Clinical Pipeline Review: What Investors Should Watch - Stock Titan
Kaixin Pharmaceuticals Inc. entered into a definitive Equity and Assets Transfer Agreement to acquire Two subsidiaries in China from CASI Pharmaceuticals, Inc. for $20 million. - marketscreener.com
CASI Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CASI Pharmaceuticals Reports Q1 2025 Results and Asset Divestiture in China - TipRanks
CASI Pharmaceuticals Sees Revenue Boost in Q1 and Advances Key Program | CASI Stock News - GuruFocus
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results - ACCESS Newswire
CASI Pharmaceuticals Exits China in $20M Deal While Posting Record 82% Revenue Growth - Stock Titan
CASI Pharmaceuticals appoints new CFO - Investing.com
CASI Pharmaceuticals appoints new CFO By Investing.com - Investing.com India
CASI Pharmaceuticals Announces CFO Transition - TipRanks
CASI Pharmaceuticals Inc Daniel Lang To Step Down From His Role As Co'S Chief Financial Officer - marketscreener.com
CASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.com - Defense World
CASI Pharmaceuticals divests equity in Chinese subsidiaries By Investing.com - Investing.com Canada
CASI Pharmaceuticals Enters Into Definitive Agreement To Divest Assets in China - citybiz
CASI to Divest Two Subsidiaries in China - marketscreener.com
CASI Pharmaceuticals (CASI) Sells Equity and Rights to Kaixin Ph - GuruFocus
CASI Pharmaceuticals Divests Chinese Assets in $20 Million Deal - TipRanks
CASI Pharmaceuticals divests equity in Chinese subsidiaries - Investing.com
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China - ACCESS Newswire
CASI Pharmaceuticals (CASI) to Release Earnings on Tuesday - Defense World
CASI Pharmaceuticals faces Nasdaq delisting over market value By Investing.com - Investing.com Nigeria
CASI Pharmaceuticals Faces Nasdaq Listing Compliance Challenge | CASI Stock News - GuruFocus
CASI Pharmaceuticals Faces Nasdaq Compliance Challenge - TipRanks
Casi Pharmaceuticals receives Nasdaq deficiency notice - TipRanks
CASI Pharmaceuticals faces Nasdaq delisting over market value - Investing.com Australia
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement - ACCESS Newswire
StockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - ACCESS Newswire
CASI Pharmaceuticals, Inc.Ordinary Shares (NQ: CASI - FinancialContent
Brokers Issue Forecasts for CASI Q1 Earnings - Defense World
StockNews.com Initiates Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
HC Wainwright Has Lowered Expectations for CASI Pharmaceuticals (NASDAQ:CASI) Stock Price - Defense World
CASI stock touches 52-week low at $1.88 amid market challenges - Investing.com
CASI Pharmaceuticals Moves to Arbitration in Dispute with Acrotech - TipRanks
CASI receives updated buyout offer for China operations - The Pharma Letter
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely - Asianet Newsable
CASI Pharma stock hits 52-week low at $1.9 amid market challenges - Investing.com Australia
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish - MSN
CASI Pharmaceuticals receives buyout proposal from CEO By Investing.com - Investing.com South Africa
CASI Pharma stock hits 52-week low at $1.9 amid market challenges By Investing.com - Investing.com South Africa
CASI Pharmaceuticals Acquires Precision Autoimmune Therapeutics - TipRanks
Casi Pharmaceuticals Inc Stock (CASI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):